Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA™ (bevacizumab-vikg)
retinal diseases
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ONS-5010/LYTENAVA™ (bevacizumab-vikg) for retinal diseases around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“The Company engaged in the FDR process after its recent Type A meeting with the Division of Ophthalmology (Division) and Office of Specialty Medicine (OSM) related to the December 30, 2025 Complete Response Letter (CRL) for the BLA for ONS-”